MissionIR Articles
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration
AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and…
-
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment
AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals,…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding
AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology
Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors
Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing…
-
Anpac Bio Continues Growth Trajectory
In recent years, advances in technology have led to demand for early cancer testing and screening methods that are less invasive and lower cost. Insurance companies have accepted that traditional testing methods are labor intensive…
-
MissionIRNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021
Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1 The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over…
-
MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Enters Strategic Collaboration to Explore Innovative Products and Medical Solutions
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced its entry into a cooperation agreement with Roche Pharmaceuticals China (“Roche”) to leverage both parties’ advantages and sources…
-
AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening
Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening…
-
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’
AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial